abs227.txt	a	compounding	feature	of	greater	than	50%	of	all	cancers	is	the	high	incidence	ofthe	cachexia	syndrome		a	complex	metabolic	disorder	characterized	by	extremeweight	loss	due	mainly	to	the	gross	depletion	of	skeletal	muscle	tissue		althoughstudies	into	the	cause	of	cancer	cachexia	has	spanned	over	multiple	decades	little	is	known	about	the	effects	of	various	cancer	treatments	themselves	oncachexia		for	example		chemotherapy	agents	induce	side	effects	such	as	nausea	andanorexia		but	these	symptoms	do	not	fully	account	for	the	changes	seen	withcancer	cachexia		in	this	study	we	examine	the	effects	of	chemotherapeuticcompounds		specifically		cisplatin	in	the	colon-26	adenocarcinoma	model	of	cancercachexia		we	find	that	although	cisplatin	is	able	to	reduce	tumor	burden	asexpected		muscle	wasting	in	mice	nevertheless	persists		strikingly		cisplatinalone	was	seen	to	regulate	muscle	atrophy		which	was	independent	of	the	commonlyimplicated	ubiquitin	proteasome	system		finally		we	show	that	cisplatin	is	ableto	induce	nf-κb	activity	in	both	mouse	muscles	and	myotube	cultures		suggestingthat	an	additional	side	effect	of	cancer	treatment	is	the	regulation	of	musclewasting	that	may	be	mediated	through	activation	of	the	nf-κb	signaling	pathway	
